Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Stemirna COVID-19 mRNA Vaccine Phase I/II Trial
NCT05144139Phase 2Completed
- Sponsor
- Stemirna Therapeutics
- Start
- Dec 2021
- Primary completion
- Aug 2022
- Modality
- Nanoparticles, Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of SW-BIC-213 in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Stemirna Therapeutics. Primary endpoints: local/systemic solicited adverse reaction/events, unsolicited adverse events and 1 more. Started Dec 2021; status: completed.
02
Drugs
SW-BIC-213
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05144139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05144139.